<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>MINOCYCLINE HYDROCHLORIDE- minocycline hydrochloride capsule </strong><br>Direct Rx<br></p></div>
<h1></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
<h1></h1>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="L596d4c1e-4f3d-4f65-a59c-ac060b938ad8"></a><a name="section-1"></a><p></p>
<h1>SPL UNCLASSIFIED SECTION</h1>
<p class="First">To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by bacteria.</p>
<p><a href="http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9013ca48-15f2-43cd-a51d-91cf65c72a7c">Close</a></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="L1ab87ab2-4a02-4d78-9e44-b6f7afbdeb65"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Minocycline hydrochloride, USP, is a semisynthetic derivative of tetracycline, 4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide monohydrochloride.</p>
<p>Its structural formula is:</p>
<div class="Figure"><img alt="image description" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=174d642b-70b1-45b0-ad33-a4847feb1a8f&amp;name=Molecule.jpg"></div>
<p>Minocycline hydrochloride capsules, USP for oral administration contain minocycline hydrochloride, USP equivalent to 50 mg, 75 mg or 100 mg of minocycline. The capsule also contains the following inactive ingredients: corn starch and magnesium stearate. The empty hard gelatin capsule shells contain titanium dioxide, sodium lauryl sulfate, and gelatin. In addition, the 50 mg capsule shells contain FD&amp;C Red #3, D&amp;C Red #33, and FD&amp;C Yellow #6; the 75 mg capsule shells contain black iron oxide; and the 100 mg capsule shells contain FD&amp;C Blue #1, D&amp;C Red #28, FD&amp;C Red #40, and red iron oxide. The capsules are printed with edible ink containing shellac, dehydrated alcohol, isopropyl alcohol, butyl alcohol, propylene glycol, strong <span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span> solution, black iron oxide, and potassium hydroxide.</p>
<p><a href="http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9013ca48-15f2-43cd-a51d-91cf65c72a7c">Close</a></p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="L1f0cb08c-485e-41bd-954b-0cfbe62e546b"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Following a single dose of two minocycline hydrochloride capsules, 100 mg administered to 18 normal fasting adult volunteers, maximum serum concentrations were attained in 1 to 4 hours (average 2.1 hours) and ranged from 2.1 to 5.1 mcg/mL (average 3.5 mcg/mL). The serum half-life in the normal volunteers ranged from 11.1 to 22.1 hours (average 15.5 hours).</p>
<p>When minocycline hydrochloride capsules were given concomitantly with a high-fat meal, which included dairy products, the extent of absorption of minocycline hydrochloride capsules was unchanged compared to dosing under fasting conditions. The mean Tmax was delayed by one hour when administered with food, compared to dosing under fasting conditions. Minocycline hydrochloride capsules may be administered with or without food.</p>
<p>In previous studies with other minocycline dosage forms, the minocycline serum half-life ranged from 11 to 16 hours in 7 patients with hepatic dysfunction, and from 18 to 69 hours in 5 patients with renal dysfunction. The urinary and fecal recovery of minocycline when administered to 12 normal volunteers was one-half to one-third that of other tetracyclines.</p>
<p>Microbiology</p>
<br><p>The tetracyclines are primarily bacteriostatic and are thought to exert their antimicrobial effect by the inhibition of protein synthesis. The tetracyclines, including minocycline, have a similar antimicrobial spectrum of activity against a wide range of gram-positive and gram-negative organisms. Cross-resistance of these organisms to tetracycline is common.</p>
<p>Minocycline has been shown to be active against most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following microorganisms, both in vitro and in clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> as described in the <a href="http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9013ca48-15f2-43cd-a51d-91cf65c72a7c#Section_3">INDICATIONS AND USAGE</a> section:</p>
<p>GRAM-POSITIVE BACTERIA </p>
<p>Because many <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following gram-positive microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are especially recommended. Tetracycline antibiotics should not be used for streptococcal diseases unless the organism has been demonstrated to be susceptible. Tetracyclines are not the drug of choice in the treatment of any type of <span class="product-label-link" type="condition" conceptid="435459" conceptname="Staphylococcal infectious disease">staphylococcal infection</span>.</p>
<p>Bacillus anthracis1 </p>
<p>Listeria monocytogenes1 </p>
<p>Staphylococcus aureus </p>
<p>Streptococcus pneumoniae </p>
<p>GRAM-NEGATIVE BACTERIA </p>
<p>Bartonella bacilliformis </p>
<p>Brucella species</p>
<p>Calymmatobacterium granulomatis </p>
<p>Campylobacter fetus </p>
<p>Francisella tularensis </p>
<p>Haemophilus ducreyi </p>
<p>Vibrio cholerae </p>
<p>Yersinia pestis </p>
<p>Because many <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following groups of gram-negative microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility tests are especially recommended. </p>
<p>Acinetobacter species</p>
<p>Enterobacter aerogenes </p>
<p>Escherichia coli </p>
<p>Haemophilus influenzae </p>
<p>Klebsiella species</p>
<p>Neisseria gonorrhoeae1 </p>
<p>Neisseria meningitidis1 </p>
<p>Shigella species</p>
<p>"OTHER" MICROORGANISMS </p>
<p>Actinomyces species1 </p>
<p>Borrelia recurrentis </p>
<p>Chlamydia psittaci </p>
<p>Chlamydia trachomatis </p>
<p>Clostridium species1 </p>
<p>Entamoeba species</p>
<p>Fusobacterium nucleatum subspecies fusiforme1 </p>
<p>Mycobacterium marinum </p>
<p>Mycoplasma pneumoniae </p>
<p>Propionibacterium <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acnes</span> </p>
<p>Rickettsiae </p>
<p>Treponema pallidum subspecies pallidum1 </p>
<p>Treponema pallidum subspecies pertenue1 </p>
<p>Ureaplasma urealyticum </p>
<p>1 When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by the cited microorganisms.</p>
<p>Susceptibility Tests</p>
<p>Susceptibility testing should be performed with tetracycline since it predicts susceptibility to minocycline. However, certain organisms (e.g., some staphylococci, and Acinetobacter species) may be more susceptible to minocycline and doxycycline than to tetracycline.</p>
<p>Dilution techniques</p>
<p>Quantitative methods are used to determine antimicrobial minimal inhibitory concentrations (MICs). These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized procedure. Standardized procedures are based on a dilution method (Ref1, Ref3) (broth or agar) or equivalent with standardized inoculum concentrations and standardized concentrations of tetracycline powder. The MIC values should be interpreted according to the following criteria:</p>
<p>For testing aerobic gram-negative microorganisms (Enterobacteriaceae), Acinetobacter spp., and Staphylococcus aureus:</p>
<table width="90%"><tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" align="center" valign="top">MIC (mcg/mL)</td>
<td class="Rrule" align="center" valign="top">Interpretation</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">≤ 4</td>
<td class="Rrule" align="center" valign="top">Susceptible (S)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">8</td>
<td class="Rrule" align="center" valign="top">Intermediate (I)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center" valign="top">≥ 16</td>
<td class="Rrule" align="center" valign="top">Resistant (R)</td>
</tr>
</tbody></table>
<br><p>For testing Haemophilus influenzae2 and Streptococcus pneumoniae3:</p>
<table width="90%"><tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" align="center" valign="top">MIC (mcg/mL)</td>
<td class="Rrule" align="center" valign="top">Interpretation</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">≤ 2</td>
<td class="Rrule" align="center" valign="top">Susceptible (S)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">4</td>
<td class="Rrule" align="center" valign="top">Intermediate (I)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center" valign="top">≥ 8</td>
<td class="Rrule" align="center" valign="top">Resistant (R)</td>
</tr>
</tbody></table>
<p>2 These interpretative standards are applicable only to broth microdilution susceptibility testing with Haemophilus influenzae using Haemophilus Test Medium.</p>
<p>3 These interpretative standards are applicable only to broth microdilution susceptibility testing using cation-adjusted Mueller-Hinton broth with 2 to 5% lysed horse blood.</p>
<p>For testing Neisseria gonorrhoeae4:</p>
<table width="90%"><tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" align="center" valign="top">MIC (mcg/mL)</td>
<td class="Rrule" align="center" valign="top">Interpretation</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">≤ 0.25</td>
<td class="Rrule" align="center" valign="top">Susceptible (S)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">0.5 to 1</td>
<td class="Rrule" align="center" valign="top">Intermediate (I)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center" valign="top">≥ 2</td>
<td class="Rrule" align="center" valign="top">Resistant (R)</td>
</tr>
</tbody></table>
<br><p>4 These interpretative standards are applicable only to agar dilution susceptibility testing using GC agar base and 1% defined growth supplements.</p>
<p>A report of "Susceptible" indicates that the pathogen is likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable. A report of "Intermediate" indicates that the result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where high dosage of drug can be used. This category also provides a buffer zone which prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of "Resistant" indicates that the pathogen is not likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable; other therapy should be selected.</p>
<p>Quality Control</p>
<p>Standardized susceptibility test procedures require the use of laboratory control microorganisms to control the technical aspects of the laboratory procedures. Standard tetracycline powder should provide the following MIC values:</p>
<table width="86%"><tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" align="center" valign="top">Microorganism</td>
<td class="Rrule" align="center" valign="top">MIC Range (mcg/mL)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">Escherichia coli ATCC 25922</td>
<td class="Rrule" align="center" valign="top">0.5 to 2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">Staphylococcus aureus ATCC 29213</td>
<td class="Rrule" align="center" valign="top">0.12 to 1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">Haemophilus influenzae ATCC 49247</td>
<td class="Rrule" align="center" valign="top">4 to 32</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">Streptococcus pneumoniae ATCC 49619</td>
<td class="Rrule" align="center" valign="top">0.06 to 0.5</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center" valign="top">Neisseria gonorrhoeae ATCC 49226</td>
<td class="Rrule" align="center" valign="top">0.25 to 1</td>
</tr>
</tbody></table>
<p></p>
<p>Diffusion techniques</p>
<p>Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. One such standardized procedure Ref2, Ref3 requires the use of standardized inoculum concentrations. This procedure uses paper disks impregnated with 30 mcg tetracycline (class disk) or 30 mcg minocycline to test the susceptibility of microorganisms to minocycline.</p>
<p>Reports from the laboratory providing results of the standard single-disk susceptibility test with a 30 mcg tetracycline or minocycline disk should be interpreted according to the following criteria:</p>
<p>For testing aerobic Enterobacteriaceae and Acinetobacter spp.:</p>
<table width="90%"><tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" align="center" valign="top">Zone Diameter (mm)</td>
<td class="Rrule" align="center" valign="top">Interpretation</td>
<td class="Rrule" align="center" valign="top">MIC (mcg/mL)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">≥16</td>
<td class="Rrule" align="center" valign="top">Susceptible (S)</td>
<td class="Rrule" align="center" valign="top">≤ 4</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">13 to 15</td>
<td class="Rrule" align="center" valign="top">Intermediate (I)</td>
<td class="Rrule" align="center" valign="top">-</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center" valign="top">≤ 12</td>
<td class="Rrule" align="center" valign="top">Resistant (R)</td>
<td class="Rrule" align="center" valign="top">≥ 16</td>
</tr>
</tbody></table>
<p>These zone diameter standards are applicable only to susceptibility testing using Mueller-Hinton agar and 30 mcg minocycline disk.</p>
<p>For testing Staphylococcus aureus:</p>
<table width="90%"><tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" align="center" valign="top">Zone Diameter (mm)</td>
<td class="Rrule" align="center" valign="top">Interpretation</td>
<td class="Rrule" align="center" valign="top">MIC (mcg/mL)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">≥19</td>
<td class="Rrule" align="center" valign="top">Susceptible (S)</td>
<td class="Rrule" align="center" valign="top">≤ 4</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">15 to 18</td>
<td class="Rrule" align="center" valign="top">Intermediate (I)</td>
<td class="Rrule" align="center" valign="top">-</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center" valign="top">≤14</td>
<td class="Rrule" align="center" valign="top">Resistant (R)</td>
<td class="Rrule" align="center" valign="top">≥ 16</td>
</tr>
</tbody></table>
<p>These zone diameter standards are applicable only to susceptibility testing using Mueller-Hinton agar and a 30 mcg minocycline disk.</p>
<p>For testing Haemophilus influenzae5:</p>
<table width="90%"><tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" align="center" valign="top">Zone Diameter (mm)</td>
<td class="Rrule" align="center" valign="top">Interpretation</td>
<td class="Rrule" align="center" valign="top">MIC (mcg/mL)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">≥ 29</td>
<td class="Rrule" align="center" valign="top">Susceptible (S)</td>
<td class="Rrule" align="center" valign="top">≤ 2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">26 to 28</td>
<td class="Rrule" align="center" valign="top">Intermediate (I)</td>
<td class="Rrule" align="center" valign="top">-</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center" valign="top">≤ 25</td>
<td class="Rrule" align="center" valign="top">Resistant (R)</td>
<td class="Rrule" align="center" valign="top">≥ 8</td>
</tr>
</tbody></table>
<p>5 These zone diameter standards are applicable only to susceptibility testing with Haemophilus influenzae using Haemophilus Test Medium and a 30 mcg tetracycline disk.</p>
<p>For testing Neisseria gonorrhoeae6:</p>
<table width="90%"><tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" align="center" valign="top">Zone Diameter (mm)</td>
<td class="Rrule" align="center" valign="top">Interpretation</td>
<td class="Rrule" align="center" valign="top">MIC (mcg/mL)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">≥ 38</td>
<td class="Rrule" align="center" valign="top">Susceptible (S)</td>
<td class="Rrule" align="center" valign="top">≤ 0.25</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">31 to 37</td>
<td class="Rrule" align="center" valign="top">Intermediate (I)</td>
<td class="Rrule" align="center" valign="top">-</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center" valign="top">≤ 30</td>
<td class="Rrule" align="center" valign="top">Resistant (R)</td>
<td class="Rrule" align="center" valign="top">≥ 2</td>
</tr>
</tbody></table>
<p>6 These interpretative standards are applicable only to disk diffusion testing using GC agar and 1% growth supplements, and a 30 mcg tetracycline disk.</p>
<p>For testing Streptococcus pneumoniae7:</p>
<table width="90%"><tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" align="center" valign="top">Zone Diameter (mm)</td>
<td class="Rrule" align="center" valign="top">Interpretation</td>
<td class="Rrule" align="center" valign="top">MIC (mcg/mL)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">≥ 23</td>
<td class="Rrule" align="center" valign="top">Susceptible (S)</td>
<td class="Rrule" align="center" valign="top">≤ 2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">19 to 22</td>
<td class="Rrule" align="center" valign="top">Intermediate (I)</td>
<td class="Rrule" align="center" valign="top">-</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center" valign="top">≤ 18</td>
<td class="Rrule" align="center" valign="top">Resistant (R)</td>
<td class="Rrule" align="center" valign="top">≥ 8</td>
</tr>
</tbody></table>
<p>7 These interpretative standards are applicable only to disk diffusion testing using Mueller-Hinton agar adjusted with 5% sheep blood and a 30 mcg tetracycline disk.</p>
<p>Interpretation should be as stated above for results using dilution techniques. Interpretation involves correlation of the diameter obtained in the disk test with the MIC for tetracycline.</p>
<p>Quality Control</p>
<p>As with standardized dilution techniques, diffusion methods require the use of laboratory control microorganisms that are used to control the technical aspects of the laboratory procedures. For the diffusion technique, the 30 mcg tetracycline or minocycline disk should provide the following zone diameters in these laboratory test quality control <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>:</p>
<table width="91%"><tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" align="center" valign="top">Microorganism</td>
<td class="Rrule" align="center" valign="top">Zone Diameter Range (mm)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top">Tetracycline</td>
<td class="Rrule" align="center" valign="top">Minocycline</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Escherichia coli ATCC 25922</td>
<td class="Rrule" align="center" valign="top">18 to 25</td>
<td class="Rrule" align="center" valign="top">19 to 25</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Staphylococcus aureus ATCC 25923</td>
<td class="Rrule" align="center" valign="top">24 to 30</td>
<td class="Rrule" align="center" valign="top">25 to 30</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Haemophilus influenzae ATCC 49247</td>
<td class="Rrule" align="center" valign="top">14 to 22</td>
<td class="Rrule" align="center" valign="top">-</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Neisseria gonorrhoeae ATCC 49226</td>
<td class="Rrule" align="center" valign="top">30 to 42</td>
<td class="Rrule" align="center" valign="top">-</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">Streptococcus pneumoniae ATCC 49619</td>
<td class="Rrule" align="center" valign="top">27 to 31</td>
<td class="Rrule" align="center" valign="top">-</td>
</tr>
</tbody></table>
<p><a href="http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9013ca48-15f2-43cd-a51d-91cf65c72a7c">Close</a></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="Lafbee887-411b-4477-b1df-9ea4bc560d46"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Minocycline hydrochloride capsules, USP are indicated in the treatment of the following <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the designated microorganisms:</p>
<p></p>
<ul class="Disc">
<li>Rocky Mountain spotted <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, typhus <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and the typhus group, Q <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, rickettsialpox and tick <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fevers</span> caused by rickettsiae.</li>
<li><span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">Respiratory tract infections</span> caused by Mycoplasma pneumoniae.</li>
<li>Lymphogranuloma venereum caused by Chlamydia trachomatis.</li>
<li>Psittacosis (Ornithosis) due to Chlamydia psittaci.</li>
<li>Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence.</li>
<li>Inclusion <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span> caused by Chlamydia trachomatis.</li>
<li>Nongonococcal <span class="product-label-link" type="condition" conceptid="195862" conceptname="Urethritis">urethritis</span>, endocervical, or rectal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis.</li>
<li><span class="product-label-link" type="condition" conceptid="440637" conceptname="Relapsing fever">Relapsing fever</span> due to Borrelia recurrentis.</li>
<li><span class="product-label-link" type="condition" conceptid="138973" conceptname="Chancroid">Chancroid</span> caused by Haemophilus ducreyi.</li>
<li><span class="product-label-link" type="condition" conceptid="434271" conceptname="Plague">Plague</span> due to Yersinia pestis.</li>
<li>Tularemia due to Francisella tularensis.</li>
<li><span class="product-label-link" type="condition" conceptid="198677" conceptname="Cholera">Cholera</span> caused by Vibrio cholerae.</li>
<li>Campylobacter fetus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by Campylobacter fetus.</li>
<li><span class="product-label-link" type="condition" conceptid="441497" conceptname="Brucellosis">Brucellosis</span> due to Brucella species (in conjunction with streptomycin).</li>
<li>Bartonellosis due to Bartonella bacilliformis.</li>
<li><span class="product-label-link" type="condition" conceptid="199726" conceptname="Granuloma inguinale">Granuloma inguinale</span> caused by Calymmatobacterium granulomatis.</li>
</ul>
<p></p>
<p>Minocycline is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug:</p>
<p></p>
<ul class="Disc">
<li> Escherichia coli.</li>
<li>Enterobacter aerogenes.</li>
<li>Shigella species. </li>
<li>Acinetobacter species.</li>
<li><span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">Respiratory tract infections</span> caused by Haemophilus influenzae.</li>
<li>Respiratory tract and <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span> caused by Klebsiella species. </li>
</ul>
<p></p>
<p>Minocycline hydrochloride capsules, USP are indicated for the treatment of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: </p>
<p></p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory tract infections</span> caused by Streptococcus pneumoniae.</li>
<li>Skin and skin structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by Staphylococcus aureus. (Note: Minocycline is not the drug of choice in the treatment of any type of <span class="product-label-link" type="condition" conceptid="435459" conceptname="Staphylococcal infectious disease">staphylococcal infection</span>.)</li>
</ul>
<p></p>
<p>When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>:</p>
<p></p>
<ul class="Disc">
<li>Uncomplicated <span class="product-label-link" type="condition" conceptid="195862" conceptname="Urethritis">urethritis</span> in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</li>
<li><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> in women caused by Neisseria gonorrhoeae.</li>
<li><span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">Syphilis</span> caused by Treponema pallidum subspecies pallidum.</li>
<li>Yaws caused by Treponema pallidum subspecies pertenue. </li>
<li><span class="product-label-link" type="condition" conceptid="438059" conceptname="Listeriosis">Listeriosis</span> due to Listeria monocytogenes. </li>
<li><span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">Anthrax</span> due to Bacillus anthracis. </li>
<li>Vincent's <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> caused by Fusobacterium fusiforme.</li>
<li><span class="product-label-link" type="condition" conceptid="436020" conceptname="Actinomycotic infection">Actinomycosis</span> caused by Actinomyces israelii. </li>
<li><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> caused by Clostridium species.  </li>
</ul>
<p></p>
<p>In acute intestinal <span class="product-label-link" type="condition" conceptid="438959" conceptname="Amebic infection">amebiasis</span>, minocycline may be a useful adjunct to amebicides.</p>
<p>In severe <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>, minocycline may be useful adjunctive therapy.</p>
<p>Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> use of minocycline be reserved for situations in which the risk of <span class="product-label-link" type="condition" conceptid="438338" conceptname="Meningococcal meningitis">meningococcal meningitis</span> is high.</p>
<p>Oral minocycline is not indicated for the treatment of <span class="product-label-link" type="condition" conceptid="436621" conceptname="Meningococcal infectious disease">meningococcal infection</span>. </p>
<p>Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by Mycobacterium marinum.</p>
<p>To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules, USP and other antibacterial drugs, minocycline hydrochloride capsules, USP should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</p>
<p><a href="http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9013ca48-15f2-43cd-a51d-91cf65c72a7c">Close</a></p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="Lbba2c603-41e0-4cf2-b49a-57d1d446461a"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">This drug is contraindicated in persons who have shown <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any of the tetracyclines or to any of the components of the product formulation.</p>
<p><a href="http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9013ca48-15f2-43cd-a51d-91cf65c72a7c">Close</a></p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="La02399e3-a381-4fad-8c87-fc7f06461a46"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First"><span class="Bold">MINOCYCLINE HYDROCHLORIDE CAPSULES, LIKE OTHER TETRACYCLINE-CLASS ANTIBIOTICS, CAN CAUSE FETAL HARM WHEN ADMINISTERED TO A PREGNANT WOMAN. IF ANY TETRACYCLINE IS USED DURING PREGNANCY OR IF THE PATIENT BECOMES PREGNANT WHILE TAKING THESE DRUGS, THE PATIENT SHOULD BE APPRISED OF THE POTENTIAL HAZARD TO THE FETUS. THE USE OF DRUGS OF THE TETRACYCLINE CLASS DURING TOOTH DEVELOPMENT (LAST HALF OF PREGNANCY, INFANCY, AND CHILDHOOD TO THE AGE OF 8 YEARS) MAY CAUSE PERMANENT DISCOLORATION OF THE TEETH (YELLOW-GRAY-BROWN). </span></p>
<p>This adverse reaction is more common during long-term use of the drug but has been observed following repeated short-term courses. <span class="product-label-link" type="condition" conceptid="4131814" conceptname="Enamel hypoplasia">Enamel hypoplasia</span> has also been reported.<span class="Bold"> TETRACYCLINE DRUGS, THEREFORE, SHOULD NOT BE USED DURING TOOTH DEVELOPMENT UNLESS OTHER DRUGS ARE NOT LIKELY TO BE EFFECTIVE OR ARE CONTRAINDICATED.</span></p>
<p>All tetracyclines form a stable calcium complex in any bone-forming tissue. A decrease in the fibula growth rate has been observed in premature human infants given oral tetracycline in doses of 25 mg/kg every six hours. This reaction was shown to be reversible when the drug was discontinued.</p>
<p>Results of animal studies indicate that tetracyclines cross the placenta, are found in fetal tissues, and can have toxic effects on the developing fetus (often related to retardation of skeletal development). Evidence of embryotoxicity has been noted in animals treated early in pregnancy.</p>
<p><span class="product-label-link" type="condition" conceptid="4080559" conceptname="Baboon syndrome">Drug Rash</span> with <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">Eosinophilia</span> and Systemic Symptoms (DRESS) including fatal cases have been reported with minocycline use. If this syndrome is recognized, the drug should be discontinued immediately.</p>
<p>The anti-anabolic action of the tetracyclines may cause an increase in BUN. While this is not a problem in those with normal renal function, in patients with significantly impaired function, higher serum levels of tetracycline may lead to <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span>, <span class="product-label-link" type="condition" conceptid="4065502" conceptname="Hyperphosphatemia">hyperphosphatemia</span>, and <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span>. Under such conditions, monitoring of creatinine and BUN is recommended, and the total daily dosage should not exceed 200 mg in 24 hours. (See <a href="http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9013ca48-15f2-43cd-a51d-91cf65c72a7c#Section_10">DOSAGE AND ADMINISTRATION</a>.) If <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> exists, even usual oral or parenteral doses may lead to systemic accumulation of the drug and possible liver toxicity.</p>
<p><span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">Photosensitivity</span> manifested by an exaggerated sunburn reaction has been observed in some individuals taking tetracyclines. This has been reported with minocycline.</p>
<p>Central nervous system side effects including light-headedness, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, or <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span> have been reported with minocycline therapy. Patients who experience these symptoms should be cautioned about driving vehicles or using hazardous machinery while on minocycline therapy. These symptoms may disappear during therapy and usually disappear rapidly when the drug is discontinued. </p>
<p>Clostridium difficile associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (CDAD) has been reported with use of nearly all antibacterial agents, including minocycline hydrochloride, and may range in severity from mild <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> to fatal <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile. </p>
<p>C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of C. difficile cause increased morbidity and mortality, as these <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. </p>
<p>If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.</p>
<p><a href="http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9013ca48-15f2-43cd-a51d-91cf65c72a7c">Close</a></p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="L69893490-4013-4ac2-9f71-f0d4c56c5098"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First">General</p>
<br><p>As with other antibiotic preparations, use of this drug may result in overgrowth of non-susceptible organisms, including fungi. If <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfection</span> occurs, the antibiotic should be discontinued and appropriate therapy instituted.</p>
<p><span class="product-label-link" type="condition" conceptid="312902" conceptname="Benign intracranial hypertension">Pseudotumor cerebri</span> (<span class="product-label-link" type="condition" conceptid="312902" conceptname="Benign intracranial hypertension">benign intracranial hypertension</span>) in adults has been associated with the use of tetracyclines. The usual clinical manifestations are <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> and <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>. Bulging fontanels have been associated with the use of tetracyclines in infants. While both of these conditions and related symptoms usually resolve after discontinuation of the tetracycline, the possibility for permanent sequelae exists.</p>
<p>Hepatotoxicity has been reported with minocycline; therefore, minocycline should be used with caution in patients with hepatic dysfunction and in conjunction with other hepatotoxic drugs.</p>
<p>Incision and drainage or other surgical procedures should be performed in conjunction with antibiotic therapy when indicated.</p>
<p>Prescribing minocycline hydrochloride capsules in the absence of a proven or strongly suspected <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> or a <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.</p>
<p>Information For Patients</p>
<br><p><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">bloody stools</span> (with or without <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach cramps</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>) even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible.</p>
<p><span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">Photosensitivity</span> manifested by an exaggerated sunburn reaction has been observed in some individuals taking tetracyclines. Patients apt to be exposed to direct sunlight or ultraviolet light should be advised that this reaction can occur with tetracycline drugs, and treatment should be discontinued at the first evidence of <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">skin erythema</span>. This reaction has been reported with use of minocycline.</p>
<p>Patients who experience central nervous system symptoms should be cautioned about driving vehicles or using hazardous machinery while on minocycline therapy. (See <a href="http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9013ca48-15f2-43cd-a51d-91cf65c72a7c#Section_5">WARNINGS</a>.)</p>
<p>Concurrent use of tetracycline with oral contraceptives may render oral contraceptives less effective. (See <a href="http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9013ca48-15f2-43cd-a51d-91cf65c72a7c#Section_6.4">Drug Interactions</a>.)</p>
<p>Patients should be counseled that antibacterial drugs including minocycline hydrochloride capsules should only be used to treat <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>. They do not treat <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> (e.g., the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>). When minocycline hydrochloride capsules are prescribed to treat a <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span>, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by minocycline hydrochloride capsules or other antibacterial drugs in the future.</p>
<p>Unused supplies of tetracycline antibiotics should be discarded by the expiration date.</p>
<p>Laboratory Tests</p>
<br><p>In venereal disease when coexistent <span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">syphilis</span> is suspected, a dark-field examination should be done before treatment is started and the blood serology repeated monthly for at least four months.</p>
<p>Periodic laboratory evaluations of organ systems, including hematopoietic, renal, and hepatic, should be performed.</p>
<p>Drug Interactions</p>
<br><p>Because tetracyclines have been shown to depress plasma <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.</p>
<p>Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracycline-class drugs in conjunction with penicillin.</p>
<p>Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.</p>
<p>The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity.</p>
<p>Concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective.</p>
<p>Administration of isotretinoin should be avoided shortly before, during, and shortly after minocycline therapy. Each drug alone has been associated with <span class="product-label-link" type="condition" conceptid="312902" conceptname="Benign intracranial hypertension">pseudotumor cerebri</span>. (See <a href="http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9013ca48-15f2-43cd-a51d-91cf65c72a7c#Section_6">PRECAUTIONS</a>.)</p>
<p>Increased risk of <span class="product-label-link" type="condition" conceptid="4201303" conceptname="Ergotism">ergotism</span> when ergot alkaloids or their derivatives are given with tetracyclines.</p>
<p>Drug/Laboratory Test Interactions</p>
<br><p>False elevations of urinary catecholamine levels may occur due to interference with the fluorescence test.</p>
<p>Carcinogenesis, Mutagenesis, Impairment of Fertility</p>
<br><p>Dietary administration of minocycline in long-term tumorigenicity studies in rats resulted in evidence of <span class="product-label-link" type="condition" conceptid="4030041" conceptname="Thyroid nodule">thyroid tumor</span> production. Minocycline has also been found to produce <span class="product-label-link" type="condition" conceptid="135772" conceptname="Goiter">thyroid hyperplasia</span> in rats and dogs. In addition, there has been evidence of oncogenic activity in rats in studies with a related antibiotic, oxytetracycline (i.e., adrenal and pituitary tumors). Likewise, although mutagenicity studies of minocycline have not been conducted, positive results in in vitro mammalian cell assays (i.e., mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> and Chinese hamster lung cells) have been reported for related antibiotics (tetracycline hydrochloride and oxytetracycline). Segment I (fertility and general reproduction) studies have provided evidence that minocycline impairs fertility in male rats.</p>
<p>PregnancyTeratogenic Effects</p>
<br><p>Pregnancy Category D. (See <a href="http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9013ca48-15f2-43cd-a51d-91cf65c72a7c#Section_5">WARNINGS</a>.)</p>
<p>All pregnancies have a background risk of <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span>, loss, or other adverse outcome regardless of drug exposure. There are no adequate and well-controlled studies on the use of minocycline in pregnant women. Minocycline, like other tetracycline-class antibiotics, crosses the placenta and may cause fetal harm when administered to a pregnant woman. Rare spontaneous reports of congenital anomalies including limb reduction have been reported in postmarketing experience. Only limited information is available regarding these reports; therefore, no conclusion on causal association can be established. If minocycline is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.</p>
<p>Nonteratogenic Effects</p>
<br><p>(See <a href="http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9013ca48-15f2-43cd-a51d-91cf65c72a7c#Section_5">WARNINGS</a>.)</p>
<p>Labor and Delivery</p>
<br><p>The effect of tetracyclines on labor and delivery is unknown.</p>
<p>Nursing Mothers</p>
<br><p>Tetracyclines are excreted in human milk. Because of the potential for serious adverse reactions in nursing infants from the tetracyclines, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. (See <a href="http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9013ca48-15f2-43cd-a51d-91cf65c72a7c#Section_5">WARNINGS</a>.)</p>
<p>Pediatric Use</p>
<br><p>Minocycline is not recommended for the use in children below 8 years of age unless the expected benefits of therapy outweigh the risks. (See <a href="http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9013ca48-15f2-43cd-a51d-91cf65c72a7c#Section_5">WARNINGS</a>.)</p>
<p>Geriatric Use</p>
<br><p>Clinical studies of oral minocycline did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. (See <a href="http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9013ca48-15f2-43cd-a51d-91cf65c72a7c#Section_5">WARNINGS</a>, <a href="http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9013ca48-15f2-43cd-a51d-91cf65c72a7c#Section_10">DOSAGE AND ADMINISTRATION</a>.)</p>
<p><a href="http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9013ca48-15f2-43cd-a51d-91cf65c72a7c">Close</a></p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="Lb9ca5d27-a546-43ed-b2eb-daeb1a5c450c"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Due to oral minocycline's virtually complete absorption, side effects to the lower bowel, particularly <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, have been infrequent. The following adverse reactions have been observed in patients receiving tetracyclines. </p>
<p>Body as a whole:  <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span>, and discoloration of secretions. </p>
<p>Gastrointestinal:  <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>, <span class="product-label-link" type="condition" conceptid="436147" conceptname="Glossitis">glossitis</span>, <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>, <span class="product-label-link" type="condition" conceptid="4131814" conceptname="Enamel hypoplasia">enamel hypoplasia</span>, <span class="product-label-link" type="condition" conceptid="4184503" conceptname="Enterocolitis">enterocolitis</span>, <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, inflammatory lesions (with monilial overgrowth) in the oral and anogenital regions. Instances of <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span> and <span class="product-label-link" type="condition" conceptid="25844" conceptname="Ulcer of esophagus">esophageal ulcerations</span> have been reported in patients taking the tetracycline-class antibiotics in capsule and tablet form. Most of these patients took the medication immediately before going to bed. (See <a href="http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9013ca48-15f2-43cd-a51d-91cf65c72a7c#Section_10">DOSAGE AND ADMINISTRATION</a>.) </p>
<p>Genitourinary:  <span class="product-label-link" type="condition" conceptid="4180978" conceptname="Vulvovaginitis">Vulvovaginitis</span>. </p>
<p>Hepatic toxicity:  <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">Hyperbilirubinemia</span>, hepatic <span class="product-label-link" type="condition" conceptid="4143915" conceptname="Cholestasis">cholestasis</span>, increases in liver enzymes, fatal <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>, and <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>. <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span>, including <span class="product-label-link" type="condition" conceptid="200762" conceptname="Autoimmune hepatitis">autoimmune hepatitis</span>, and <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span> have been reported. (See <a href="http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9013ca48-15f2-43cd-a51d-91cf65c72a7c#Section_6">PRECAUTIONS</a>.) </p>
<p>Skin:  <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span>, <span class="product-label-link" type="condition" conceptid="140176" conceptname="Erythema nodosum">erythema nodosum</span>, hyperpigmentation of nails, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, and <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span>. Maculopapular and erythematous <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rashes</span>. <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">Exfoliative dermatitis</span> has been reported. <span class="product-label-link" type="condition" conceptid="4080559" conceptname="Baboon syndrome">Fixed drug eruptions</span> have been reported. Lesions occurring on the glans penis have caused <span class="product-label-link" type="condition" conceptid="436466" conceptname="Balanoposthitis">balanitis</span>. <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">Erythema multiforme</span> and <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span> have been reported. <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">Photosensitivity</span> is discussed above. (See <a href="http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9013ca48-15f2-43cd-a51d-91cf65c72a7c#Section_5">WARNINGS</a>.) <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">Pigmentation</span> of the skin and mucous membranes has been reported. </p>
<p>Respiratory:  <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="257581" conceptname="Exacerbation of asthma">exacerbation of asthma</span>, and <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span>. </p>
<p>Renal toxicity:  Interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span>. Elevations in BUN have been reported and are apparently dose related. (See <a href="http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9013ca48-15f2-43cd-a51d-91cf65c72a7c#Section_5">WARNINGS</a>.) Reversible <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> has been reported. </p>
<p>Musculoskeletal:  <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span>, <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>, bone discoloration, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="72404" conceptname="Joint stiffness">joint stiffness</span>, and <span class="product-label-link" type="condition" conceptid="4154927" conceptname="Joint swelling">joint swelling</span>. </p>
<p><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span>:  <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">Urticaria</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioneurotic edema</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">polyarthralgia</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>/<span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reaction</span> (including <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> and fatalities), <span class="product-label-link" type="condition" conceptid="4101602" conceptname="Henoch-Schonlein purpura">anaphylactoid purpura</span>, <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">myocarditis</span>, <span class="product-label-link" type="condition" conceptid="4138837" conceptname="Pericarditis">pericarditis</span>, exacerbation of <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span> and pulmonary infiltrates with <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span> have been reported. A transient lupus-like syndrome and <span class="product-label-link" type="condition" conceptid="432522" conceptname="Transfusion reaction due to serum protein reaction">serum sickness</span>-like reactions also have been reported. </p>
<p>Blood:  <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, and <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span> have been reported. </p>
<p>Central Nervous System:  <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypesthesia</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, sedation, and <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>. Bulging fontanels in infants and <span class="product-label-link" type="condition" conceptid="312902" conceptname="Benign intracranial hypertension">benign intracranial hypertension</span> (<span class="product-label-link" type="condition" conceptid="312902" conceptname="Benign intracranial hypertension">pseudotumor cerebri</span>) in adults have been reported. (See <a href="http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9013ca48-15f2-43cd-a51d-91cf65c72a7c#Section_6.1">PRECAUTIONS - General</a>.) <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> has also been reported.  </p>
<p>Other:  Thyroid cancer has been reported in the postmarketing setting in association with minocycline products. When minocycline therapy is given over <span class="product-label-link" type="condition" conceptid="4088438" conceptname="Prolonged periods">prolonged periods</span>, monitoring for signs of thyroid cancer should be considered. When given over <span class="product-label-link" type="condition" conceptid="4088438" conceptname="Prolonged periods">prolonged periods</span>, tetracyclines have been reported to produce brown-black microscopic discoloration of the thyroid gland. Cases of abnormal thyroid function have been reported.</p>
<p><span class="product-label-link" type="condition" conceptid="45757361" conceptname="Mottled teeth">Tooth discoloration</span> in children less than 8 years of age (see <a href="http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9013ca48-15f2-43cd-a51d-91cf65c72a7c#Section_5">WARNINGS</a>) and also, in adults has been reported.</p>
<p>Oral cavity discoloration (including tongue, lip, and gum) have been reported.</p>
<p><span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">Tinnitus</span> and decreased hearing have been reported in patients on minocycline hydrochloride.</p>
<p>The following syndromes have been reported. In some cases involving these syndromes, <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> has been reported. As with other serious adverse reactions, if any of these syndromes are recognized, the drug should be discontinued immediately:</p>
<p><span class="product-label-link" type="condition" conceptid="45765791" conceptname="Drug reaction with eosinophilia and systemic symptoms">Hypersensitivity syndrome</span> consisting of cutaneous reaction (such as <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>), <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, and one or more of the following: <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span>, <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span>, <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">myocarditis</span>, and <span class="product-label-link" type="condition" conceptid="4138837" conceptname="Pericarditis">pericarditis</span>. <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> and <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span> may be present.</p>
<p>Lupus-like syndrome consisting of positive <span class="product-label-link" type="condition" conceptid="4163958" conceptname="Antinuclear antibody">antinuclear antibody</span>; <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>, <span class="product-label-link" type="condition" conceptid="72404" conceptname="Joint stiffness">joint stiffness</span>, or <span class="product-label-link" type="condition" conceptid="4154927" conceptname="Joint swelling">joint swelling</span>; and one or more of the following: <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, and <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="432522" conceptname="Transfusion reaction due to serum protein reaction">Serum sickness</span>-like syndrome consisting of <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>; <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> or <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>; and <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>, <span class="product-label-link" type="condition" conceptid="72404" conceptname="Joint stiffness">joint stiffness</span>, or <span class="product-label-link" type="condition" conceptid="4154927" conceptname="Joint swelling">joint swelling</span>. <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">Eosinophilia</span> may be present.</p>
<p><a href="http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9013ca48-15f2-43cd-a51d-91cf65c72a7c">Close</a></p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="Lf0e26667-694f-45ce-8e69-8ec39d5ed5c3"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">The adverse events more commonly seen in <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> are <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.</p>
<p>No specific antidote for minocycline is known.</p>
<p>In case of overdosage, discontinue medication, treat symptomatically, and institute supportive measures. Minocycline is not removed in significant quantities by hemodialysis or peritoneal dialysis.</p>
<p><a href="http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9013ca48-15f2-43cd-a51d-91cf65c72a7c">Close</a></p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="L6574eaab-8701-4fa4-a595-f7eb252aa0a8"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First"></p>
<p><span class="Bold">THE USUAL DOSAGE AND FREQUENCY OF ADMINISTRATION OF MINOCYCLINE DIFFERS FROM THAT OF THE OTHER TETRACYCLINES. EXCEEDING THE RECOMMENDED DOSAGE MAY RESULT IN AN INCREASED INCIDENCE OF SIDE EFFECTS.</span></p>
<p>Minocycline hydrochloride capsules may be taken with or without food (See <a href="http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9013ca48-15f2-43cd-a51d-91cf65c72a7c#Section_2">CLINICAL PHARMACOLOGY</a>.)</p>
<p>Ingestion of adequate amounts of fluids along with capsule and tablet forms of drugs in the tetracycline-class is recommended to reduce the risk of esophageal irritation and ulceration. The capsules should be swallowed whole.</p>
<p>For Pediatric Patients Above 8 Years Of Age </p>
<p>Usual pediatric dose: 4 mg/kg initially followed by 2 mg/kg every 12 hours, not to exceed the usual adult dose.</p>
<p>Adults</p>
<br><p>The usual dosage of minocycline hydrochloride capsules is 200 mg initially followed by 100 mg every 12 hours. Alternatively, if more frequent doses are preferred, two or four 50 mg capsules may be given initially followed by one 50 mg capsule 4 times daily.</p>
<p>Uncomplicated gonococcal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> other than <span class="product-label-link" type="condition" conceptid="195862" conceptname="Urethritis">urethritis</span> and anorectal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> in men: 200 mg initially, followed by 100 mg every 12 hours for a minimum of 4 days, with post-therapy cultures within 2 to 3 days.</p>
<p>In the treatment of uncomplicated gonococcal <span class="product-label-link" type="condition" conceptid="195862" conceptname="Urethritis">urethritis</span> in men, 100 mg every 12 hours for 5 days is recommended.</p>
<p>For the treatment of <span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">syphilis</span>, the usual dosage of minocycline hydrochloride capsules should be administered over a period of 10 to 15 days. Close follow-up, including laboratory tests, is recommended.</p>
<p>In the treatment of meningococcal carrier state, the recommended dosage is 100 mg every 12 hours for 5 days. </p>
<p>Mycobacterium marinum <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>: Although optimal doses have not been established, 100 mg every 12 hours for 6 to 8 weeks have been used successfully in a limited number of cases. </p>
<p>Uncomplicated urethral, endocervical, or rectal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> in adults caused by Chlamydia trachomatis or Ureaplasma urealyticum: 100 mg orally, every 12 hours for at least 7 days.</p>
<p>Ingestion of adequate amounts of fluids along with capsule and tablet forms of drugs in the tetracycline-class is recommended to reduce the risk of esophageal irritation and ulceration.</p>
<p>The pharmacokinetics of minocycline in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CLCR &lt;80 mL/min) have not been fully characterized. Current data are insufficient to determine if a dosage adjustment is warranted. The total daily dosage should not exceed 200 mg in 24 hours. However, due to the anti-anabolic effect of tetracyclines, BUN and creatinine should be monitored. (See <a href="http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9013ca48-15f2-43cd-a51d-91cf65c72a7c#Section_5">WARNINGS</a>.)</p>
<p><a href="http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9013ca48-15f2-43cd-a51d-91cf65c72a7c">Close</a></p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="L017788ae-6a7a-4295-87f8-f2207e966fd7"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First"></p>
<p>Minocycline Hydrochloride Capsules USP, 50 mg are Pink/Pink size ‘3’ hard gelatin capsule filled with yellow granular powder and imprinted with ‘C’ on Pink cap and ‘76’ on Pink body with black ink.</p>
<p>               Bottles of 100               NDC 65862-209-01</p>
<p>               Bottles of 500               NDC 65862-209-05</p>
<p>               Bottles of 1000             NDC 65862-209-99 </p>
<p>Minocycline Hydrochloride Capsules USP, 75 mg are White/Grey size ‘3’ hard gelatin capsule filled with yellow granular powder and imprinted with ‘C’ on White cap and ‘77’ on Grey body with black ink.</p>
<p>               Bottles of 100                NDC 65862-210-01</p>
<p>               Bottles of 500                NDC 65862-210-05</p>
<p>               Bottles of 1000              NDC 65862-210-99 </p>
<p>Minocycline Hydrochloride Capsules USP, 100 mg are Maroon/Pink size ‘2’ hard gelatin capsule filled with yellow granular powder and imprinted with ‘C’ on Maroon cap and ‘78’ on Pink body with black ink.</p>
<p>               Bottles of 50                  NDC 65862-211-50</p>
<p>               Bottles of 500                NDC 65862-211-05</p>
<p>               Bottles of 1000              NDC 65862-211-99</p>
<p>Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. Protect from light, moisture and excessive heat. Dispense in a tight, light-resistant container as defined in the USP.</p>
<p><a href="http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9013ca48-15f2-43cd-a51d-91cf65c72a7c">Close</a></p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="Le05eabc0-ef4b-4fb6-9216-c3dfb645571b"></a><a name="section-12"></a><p></p>
<h1>ANIMAL PHARMACOLOGY AND TOXICOLOGY</h1>
<p class="First">Minocycline hydrochloride has been observed to cause a dark discoloration of the thyroid in experimental animals (rats, minipigs, dogs, and monkeys). In the rat, chronic treatment with minocycline hydrochloride has resulted in <span class="product-label-link" type="condition" conceptid="135772" conceptname="Goiter">goiter</span> accompanied by elevated radioactive iodine uptake and evidence of <span class="product-label-link" type="condition" conceptid="4030041" conceptname="Thyroid nodule">thyroid tumor</span> production. Minocycline hydrochloride has also been found to produce <span class="product-label-link" type="condition" conceptid="135772" conceptname="Goiter">thyroid hyperplasia</span> in rats and dogs.</p>
<p><a href="http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9013ca48-15f2-43cd-a51d-91cf65c72a7c">Close</a></p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="L74310bb7-d98e-48ef-ae71-e7869c202e56"></a><a name="section-13"></a><p></p>
<h1>REFERENCES</h1>
<p class="First">Ref1. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; Approved Standard-Ninth Edition; Document M07-A9, Vol. 32, No. 2, CLSI, Wayne, PA, January, 2012</p>
<p>Ref2.  Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard-Eleventh Edition; Document M02-A11, Vol. 32, No. 1, CLSI, Wayne, PA, January, 2012</p>
<p>Ref3. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Second Informational Supplement. Document M100-S22, Vol. 32, No. 3, CLSI, Wayne, PA, January, 2012</p>
<p>For more information, you can call Aurobindo Pharma USA, Inc. at 1-866-850-2876 (toll–free). Monday through Friday from 9:00 a.m. to 3:00 p.m. Eastern Time.</p>
<p>Manufactured for:</p>
<p>Aurobindo Pharma USA, Inc.</p>
<p>2400 Route 130 North</p>
<p>Dayton, NJ 08810</p>
<p>Manufactured by:</p>
<p>Aurobindo Pharma Limited</p>
<p>Hyderabad–500 072, India</p>
<p>Revised: 03/2014</p>
<p><a href="http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9013ca48-15f2-43cd-a51d-91cf65c72a7c">Close</a></p>
</div>
<div class="Section" data-sectionCode="68498-5">
<a name="L439eb452-92d6-4465-a288-07af6cc2015e"></a><a name="section-14"></a><p></p>
<h1>PATIENT INFORMATION ABOUT</h1>
<p class="First">Minocycline Hydrochloride Capsules, USP</p>
<p>(min'' oh sye' kleen hye'' droe klor' ide)</p>
<p>Rx only</p>
<p>Read the Patient Information that comes with minocycline hydrochloride capsules before you or a family member starts taking them and each time you get a refill. There may be new information. This leaflet does not take the place of talking to your doctor about your medical condition or treatment.</p>
<p>What are minocycline hydrochloride capsules?</p>
<p>Minocycline hydrochloride capsules are a tetracycline-class antibiotic medicine. Minocycline hydrochloride capsules are used to treat certain <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by bacteria. These include <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> of the skin, respiratory tract, urinary tract, some <span class="product-label-link" type="condition" conceptid="440647" conceptname="Sexually transmitted infectious disease">sexually transmitted diseases</span>, and others. Minocycline hydrochloride capsules may be used along with other treatments for severe <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>.</p>
<p>Sometimes, other germs, called viruses cause <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. The <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span> is a virus. Minocycline hydrochloride capsules, like other antibiotics, do not treat viruses.</p>
<p>Who should not use minocycline hydrochloride capsules?</p>
<p>Do not take minocycline hydrochloride capsules if you are allergic to minocycline or other tetracycline antibiotics.</p>
<p>Ask your doctor or pharmacist for a list of these medications if you are not sure. See the end of this leaflet for a complete list of ingredients in minocycline hydrochloride capsules.</p>
<p>Minocycline hydrochloride capsules are not recommended for pregnant women or children up to 8 years old because:</p>
<ol class="Arabic">
<li>Minocycline hydrochloride capsules may harm an unborn baby</li>
<li>Minocycline hydrochloride capsules may permanently turn a baby's or child's teeth yellow-gray-brown during tooth development. Tooth development happens in the last half of pregnancy and birth to age 8 years.</li>
</ol>
<p>What should I tell my doctor before starting minocycline hydrochloride capsules?</p>
<p>Tell your doctor about all of your medical conditions, including if you:</p>
<ul class="Disc">
<li>have liver or kidney problems</li>
<li>are pregnant or planning to become pregnant. Minocycline hydrochloride capsules may harm your unborn baby. Stop taking minocycline hydrochloride capsules and call your doctor if you become pregnant while taking them.</li>
<li>are breast feeding. Minocycline passes into your milk and may harm your baby. You should decide whether to use minocycline hydrochloride capsules or breastfeed, but not both.</li>
</ul>
<p>Tell your doctor about all the medicines you are taking including prescription and non prescription medications, vitamins, and herbal supplements. Minocycline hydrochloride capsules and other medicines may interact. Especially tell your doctor if you take:</p>
<p></p>
<ul class="Disc">
<li>birth control pills. Minocycline hydrochloride capsules may make your birth control pills less effective</li>
<li>a blood thinner medicine. The dose of your blood thinner may have to be lowered.</li>
<li>a penicillin antibiotic medicine. Minocycline hydrochloride capsules and penicillins should not be used together.</li>
<li><span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span> medicines called ergot alkaloids</li>
<li>An <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> medicine called isotretinoin (Accutane, Amnesteem, Claravis, Sotret)</li>
<li>Antacids that contain aluminum, calcium, or magnesium, or iron-containing products.</li>
</ul>
<p>Know the medicines you take, keep a list of them to show your doctor and pharmacist each time you get a new medicine.</p>
<p>How should I take minocycline hydrochloride capsules?</p>
<ul class="Disc"><li>Take minocycline hydrochloride capsules exactly as your doctor tells you to take them. Skipping doses or not taking all your minocycline hydrochloride capsules may:<ul class="Disc">
<li>Decrease the effectiveness of the treatment</li>
<li>Increase the chance that bacteria will develop resistance to minocycline hydrochloride capsules</li>
<li>Take minocycline hydrochloride capsules with a full glass of liquid. Taking minocycline hydrochloride capsules with enough liquid may lower your chance of getting irritation or <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> in your esophagus. Your esophagus is the tube that connects your mouth to your stomach.</li>
<li>Minocycline hydrochloride capsules may be taken with or without food. If you forget to take minocycline hydrochloride capsules, take them as soon as you remember.</li>
<li>If you take too many minocycline hydrochloride capsules, call your doctor or poison control center right away.</li>
</ul>
</li></ul>
<p>What are the possible side effects of minocycline hydrochloride capsules?</p>
<p>Minocycline hydrochloride capsules may cause serious side effects. Stop minocycline hydrochloride  capsules and call your doctor if you have:</p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">watery diarrhea</span></li>
<li><span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">bloody stools</span></li>
<li><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach cramps</span></li>
<li>unusual <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span></li>
<li><span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span></li>
<li><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span></li>
<li><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span></li>
<li><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span></li>
<li>feeling very tired</li>
</ul>
<p>Minocycline hydrochloride capsules may also cause:</p>
<ul class="Disc">
<li>central nervous system effects. Symptoms include light-headedness, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, and a spinning feeling (<span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>). You should not drive or operate machines if you have these symptoms.</li>
<li><span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">sun sensitivity</span> (<span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>). You may get a worse sunburn with minocycline hydrochloride capsules. Avoid sun exposure and the use of sunlamps or tanning beds. Protect your skin while out in the sunlight. Stop minocycline hydrochloride capsules and call your doctor if your skin turns red.</li>
</ul>
<p>These are not all the side effects with minocycline hydrochloride capsules. Ask your doctor or pharmacist for more information.</p>
<p>How should I store minocycline hydrochloride capsules?</p>
<ul class="Disc">
<li>Store minocycline hydrochloride capsules at room temperature and away from excess heat and moisture.</li>
<li>Throw away any minocycline hydrochloride capsules that are outdated or no longer needed.</li>
<li>Keep minocycline hydrochloride capsules and all medicines out of the reach of children.</li>
</ul>
<p>General advice about minocycline hydrochloride capsules</p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use minocycline hydrochloride capsules for a condition for which they were not prescribed. Do not give minocycline hydrochloride capsules to other people, even if they have the same symptoms you have. They may harm them.</p>
<p>This Patient Information leaflet summarizes the most important information about minocycline hydrochloride capsules. If you would like more information, talk with your doctor.</p>
<p>Your doctor or pharmacist can give you information about minocycline hydrochloride capsules that is written for health care professionals. For more information, you can also call Aurobindo Pharma USA, Inc. at 1-866-850-2876 (toll–free). Monday through Friday from 9:00 a.m. to 3:00 p.m. Eastern Time.</p>
<p>What are the ingredients in minocycline hydrochloride capsules?</p>
<p>Active ingredient: minocycline hydrochloride, USP, 50 mg, 75 mg, and 100 mg</p>
<p>Inactive ingredients: Corn starch and magnesium stearate. The empty hard gelatin capsule shells contain titanium dioxide, sodium lauryl sulfate, and gelatin. In addition, the 50 mg capsule shells contain FD&amp;C Red #3, D&amp;C Red #33, and FD&amp;C Yellow #6; the 75 mg capsule shells contain black iron oxide; and the 100 mg capsule shells contain FD&amp;C Blue #1, D&amp;C Red #28, FD&amp;C Red #40, and red iron oxide. The capsules are printed with edible ink containing shellac, dehydrated alcohol, isopropyl alcohol, butyl alcohol, propylene glycol, strong <span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span> solution, black iron oxide, and potassium hydroxide.</p>
<p>Manufactured for:</p>
<p>Aurobindo Pharma USA, Inc.</p>
<p>2400 Route 130 North</p>
<p>Dayton, NJ 08810</p>
<p>Manufactured by:</p>
<p>Aurobindo Pharma Limited</p>
<p>Hyderabad–500 072, India</p>
<p>Revised: 03/2014</p>
<p><a href="http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9013ca48-15f2-43cd-a51d-91cf65c72a7c">Close</a></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="L57c592fe-eee2-4361-9b11-8b99ab4410e7"></a><a name="section-15"></a><p></p>
<h1></h1>
<p class="First">Label for 100MG : </p>
<p><img alt="image description" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=174d642b-70b1-45b0-ad33-a4847feb1a8f&amp;name=Label%20100mg.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>MINOCYCLINE HYDROCHLORIDE 		
					</strong><br><span class="contentTableReg">minocycline hydrochloride capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:61919-560(NDC:65862-211)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>MINOCYCLINE HYDROCHLORIDE</strong> (MINOCYCLINE) </td>
<td class="formItem">MINOCYCLINE</td>
<td class="formItem">100 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SHELLAC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ISOPROPYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>BUTYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong><span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">AMMONIA</span></strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERROSOFERRIC OXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POTASSIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>D&amp;C RED NO. 28</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C RED NO. 40</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">red</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">capsule</td>
<td class="formLabel">Size</td>
<td class="formItem">18mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">C;78</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:61919-560-20</td>
<td class="formItem">20  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:61919-560-30</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA065470</td>
<td class="formItem">01/01/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Direct Rx
							(079254320)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Direct Rx</td>
<td class="formItem"></td>
<td class="formItem">079254320</td>
<td class="formItem">repack(61919-560), relabel(61919-560)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 12/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>799fd9f2-5730-4b25-9e30-1dfb36afbbaf</div>
<div>Set id: 174d642b-70b1-45b0-ad33-a4847feb1a8f</div>
<div>Version: 1</div>
<div>Effective Time: 20141216</div>
</div>
</div> <div class="DistributorName">Direct Rx</div></p>
</body></html>
